824 filings
Page 8 of 42
CORRESP
o2ybjnamg94774
31 Jul 20
Correspondence with SEC
12:00am
UPLOAD
rzwc8
24 Jul 20
Letter from SEC
12:00am
8-K
e6zmajh5to5a
20 Jul 20
Soligenix Issues Corporate Update – Highlights Important Catalysts for Second Half of 2020
7:00am
8-K
f0ibtvcg
30 Apr 20
Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
7:05am
8-K
8mjc kd8j
13 Apr 20
Other Events
8:01am
8-K
b2bwltqfjwi5r aqzmae
10 Apr 20
Other Events
4:17pm
424B5
t8nvw8mk8tfcsm
10 Apr 20
Prospectus supplement for primary offering
4:16pm
8-K
dbhgc 84iozjp
3 Apr 20
Departure of Directors or Certain Officers
4:11pm
8-K
dwbj0d4m5a z1p23m9nm
20 Mar 20
Other Events
4:07pm
424B5
c69ssrx 3l69
20 Mar 20
Prospectus supplement for primary offering
4:06pm
8-K
3z1pq9z
19 Mar 20
Soligenix Announces Positive Top-line Results for its Pivotal Phase 3 FLASH Trial Evaluating SGX301 in Treatment of Cutaneous T-Cell Lymphoma
6:04am
8-K
tr806sigwi3zuh7x
14 Jan 20
Soligenix – Advancing to Important Inflection Points
1:05pm
8-K
lj5b 8q51plq2
3 Jan 20
Departure of Directors or Certain Officers
4:30pm
8-K
thobs2v5c
17 Dec 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:14pm